ABSTRACT

The prevalence of heart failure (HF) is on the rise due to the aging of society. Furthermore, the continuous progress and widespread adoption of screening and diagnostic strategies have led to an increase in the detection rate of HF, effectively increasing the number of patients requiring monitoring and treatment. Because HF is associated with substantial rates of mortality and morbidity, as well as high socioeconomic burden, there is an increasing need for developing specific guidelines for HF management. The Korean guidelines for the diagnosis and management of chronic HF were introduced in March 2016. However, chronic and acute heart failure (AHF) represent distinct disease entities. Here, we introduce the Korean guidelines for the management of AHF with reduced or preserved ejection fraction. Part I of this guideline covers the definition, epidemiology, and diagnosis of AHF.

Keywords: Heart failure; Guideline; Epidemiology; Diagnosis

INTRODUCTION

The number of patients with heart failure (HF) has been on the rise as a consequence of the aging of society and the improvement in screening and diagnostic techniques. Therefore, there is an increasing need for developing guidelines for the diagnosis and treatment of HF. Although guidelines for HF management have already been issued by American and European associations, many aspects of such guidelines do not reflect the domestic reality.
in Korea due to the social and anthropological characteristics of the Korean population. Thus, to help clinicians establish the best treatment plan for Korean patients with HF, it is necessary to develop specific guidelines that reflect the clinical situation in Korea. In 2012, the Korean Society of Heart Failure (KSHF) established the Guideline Writing Committee to develop the treatment guidelines for HF. The Korean guidelines for the diagnosis and management of chronic heart failure (CHF) were introduced in March 2016. However, CHF and acute heart failure (AHF) are distinct disease entities, warranting different approaches for diagnosis and treatment. Here, we introduce the Korean guidelines for the management of AHF with reduced or preserved ejection fraction (HFrEF and HFpEF, respectively). In Part I of this guideline, we discuss the definition, epidemiology, and diagnosis of AHF.

This guideline was developed based on previously issued international guidelines and amended to reflect the clinical situation in Korea. A committee of KSHF members decided on the format of the guideline, the selection of topics addressed, and the composition of the Writing Committee. To develop the guidelines, we considered all clinical studies and evidence included in the international guidelines, as well as domestic research conducted in Korean patients with HF. Members of the Writing Committee first drafted thematic manuscripts, which were then assembled and arranged according to the evidence-based scales. To ensure transparency and facilitate future revision of the guidelines, we documented the process followed for issuing a recommendation for each topic based on the gathered evidence. The guideline was drafted, reviewed by the advisory committee, and finalized after receiving endorsement from the Korean Society of Cardiology, Korean Society of Hypertension, Korean Society of Interventional Cardiology, Korean Society of Echocardiography, and Korean Society of Lipid and Atherosclerosis. While working on this guideline, the members of the Writing Committee were not affected by external influences and made every effort to exclude conflicts of interests.

The Writing Committee issued the level of recommendation upon a comprehensive analysis of evidence from studies describing real clinical experience, from surveys, from epidemiologic, observational, and randomized clinical studies, and from meta-analyses. The level of evidence and class of recommendation were defined so as to have a clear formulation, provide straightforward instructions, and be easily adopted in daily clinical practice (Tables 1 and 2).

This guideline is intended to help improve clinical practice by providing recommendations based on clinical evidence. As such, the guideline does not serve as a basis for clinical judgement. The final decision in the treatment of each patient should be made by the treating physician according to their personal opinion and judgment, while using the guideline to support these decisions.

GENERAL CONCEPTS OF ACUTE HEART FAILURE

Definition and classification of acute heart failure

Definition of acute heart failure

Patients with AHF are usually hospitalized for prompt treatment because the symptoms manifest and worsen rapidly. “Compensated HF” is usually defined as HF that responds to treatment, with symptoms stable for at least 1 month. “Acute decompensated HF” is defined as a sudden deterioration of symptoms or signs in patients with compensated HF, whereas acute presentation of HF in patients with no previous symptoms is referred to as “Acute de
**Table 1. Criteria used to judge the level of evidence and establish the class of recommendation for AHF**

| Class | Class I | Class IIa | Class IIb | Class III |
|-------|---------|-----------|-----------|-----------|
| Criterion | - Benefit >> Risk | - Benefit >> Risk | - Benefit > Risk | - No benefit or harm |
|          | - Procedure/Treatment SHOULD be performed | - Additional studies with focused objectives are needed | - Additional studies with broad objectives are needed; collecting additional registry data would be helpful | - Procedure/treatment SHOULD NOT BE PERFORMED as it is not expected to be useful or may even be harmful |
| Level A | 1) Recommendation that procedure/treatment is useful/effective | 1) Recommendation in favor of procedure or treatment being useful/effective | 1) Recommendation's usefulness/efficacy less well-established | 1) Recommendation that procedure/treatment is not useful/effective and/or may be harmful |
| - Multiple populations evaluated | 2) Sufficient evidence from multiple randomized trials or meta-analyses | 2) Some conflicting evidence from multiple randomized trials or meta-analyses | 2) Greater conflicting evidence from multiple randomized trials or meta-analyses | 2) Evidence from multiple randomized trials or meta-analyses |
| Level B | 1) Recommendation that procedure/treatment is useful/effective | 1) Recommendation in favor of procedure or treatment being useful/effective | 1) Recommendation's usefulness/efficacy less well-established | 1) Recommendation that procedure/treatment is not useful/effective and/or may be harmful |
| - Limited populations evaluated | 2) Sufficient evidence from a single randomized trial or non-randomized studies | 2) Some conflicting evidence from a single randomized trial or non-randomized studies | 2) Greater conflicting evidence from a single randomized trial or non-randomized studies | 2) Evidence from a single randomized trial or non-randomized studies |
| Level C | 1) Recommendation that procedure/treatment is useful/effective | 1) Recommendation in favor of procedure or treatment being useful/effective | 1) Recommendation's usefulness/efficacy less well-established | 1) Recommendation that procedure or treatment is not useful/effective and may be harmful |
| - Very limited populations evaluated | 2) Only expert opinions, case studies, or standards of care | 2) Only diverging expert opinions, case studies, or standards of care | 2) Only diverging expert opinions, case studies, or standards of care | 2) Only expert opinions, case studies, or standards of care |
| - Only consensus expert opinions, case studies, or standards of care | 2) Only expert opinions, case studies, or standards of care | 2) Only diverging expert opinions, case studies, or standards of care | 2) Only diverging expert opinions, case studies, or standards of care | 2) Only expert opinions, case studies, or standards of care |

**Table 2. Formulations typically used with each class of recommendation**

| Class | Formulation |
|-------|-------------|
| I     | Should be used, is recommended, is useful/beneficial |
| IIa   | Is reasonable, can be useful/beneficial |
| IIb   | May be considered reasonable |
| III   | Is not recommended, should not be performed, is potentially harmful |

novo HF." Acute myocardial infarction (AMI) is the most representative manifestation of AHF, though some patients remain asymptomatic despite decreased cardiac function or may exhibit gradual symptoms as decompensation develops.

**Classification of acute heart failure**

Although there are several ways to classify AHF, the classification based on the clinical condition at the time of admission is most useful from a practical perspective because it facilitates identification of high-risk patients and initiation of treatment according to a pre-established treat-to-target strategy. In patients with AHF, systolic blood pressure is usually preserved (90–140 mmHg) or elevated (>140 mmHg; hypertensive AHF) but may also be decreased (<90 mmHg; hypotensive AHF). Hypotensive AHF generally has poor prognosis, especially if accompanied by decreased perfusion.

Regarding causes and aggravating factors of AHF, five clinical conditions require immediate treatment: acute coronary syndrome, hypertensive emergencies, tachycardia/severe bradycardia/conduction disorders, structural heart damage, and acute pulmonary embolism.
The clinical condition is defined based on the findings of the bedside physical examination, focused mainly on clarifying the presence, nature, and degree of congestion (“wet” or “dry”) and/or tissue perfusion (“warm” or “cold”) according to the Forrester classification (
Figure 1
).

AHF patients can be classified into four groups with increasingly poor prognosis: group A, with “warm” and “dry” HF (compensated, well perfused, without congestion); group B, with “warm” and “wet” HF (well perfused but congested); group C, “cold” and “dry” HF (hypoperfused but without congestion); and group D, “cold” and “wet” HF (hypoperfused and congested).

To confirm the presence and degree of congestion, it is necessary to assess jugular venous pressure and check for ascites or peripheral edema, rales or abnormal heart sound on chest auscultation, and pulmonary edema on chest radiography. Decreased tissue perfusion can be confirmed based on decreased skin temperature, reduced urine output, and altered mentality. Pulmonary capillary wedge pressure is the best indicator of congestion, while cardiac index is the best marker of perfusion.

In patients with AMI, AHF can be classified according to the Killip classification: class I, no clinical signs of HF; class II, HF with rales in half of the lung field and with S3 gallop; class III, frank acute pulmonary edema; and class IV, cardiogenic shock, hypotension, and evidence of peripheral vasoconstriction such as cyanosis, oliguria, and diaphoresis.

**Aggravating factors, risk factors, and causes of acute heart failure**

Various aggravating factors are known to induce HF decompensation (see section 2.2. Aggravating factors). Risk factors include concomitant diseases leading to structural heart disease, including hypertension, diabetes, metabolic syndrome, and atherosclerotic disease. Risk factors of AHF comprise myocardial disorders (coronary artery disease, hypertension, myocarditis, cardiomyopathy), valvular heart diseases, pericardial diseases, endocarditis, congenital heart disease, arrhythmia, conduction disturbance, high cardiac output state (anemia, sepsis, arteriovenous fistula), and right HF.

**Figure 1.** Clinical classification of acute heart failure.

CI = cardiac index; PCWP = pulmonary capillary wedge pressure.
Epidemiology

The prevalence of AHF has been increasing in parallel with the rates of cardiovascular disease, reflecting the aging of society and widespread adoption of a westernized lifestyle. AHF is a major cause of hospitalization as well as death during hospital admission and readmission, especially among individuals aged >65 years. The prevalence of AHF continues to increase despite recent advances in medical technology and reduced in-hospital mortality rates. According to epidemiological studies conducted in the United States, more than one million hospitalizations for AHF occur annually, and hospitalization rates are expected to continue to increase over the next 20 years. Approximately 15.5 million emergency room visits due to AHF were recorded between 1992 and 2001, with an average increase of 18,500 cases per year. It is estimated that, by 2050, 20% of the population of the United States will consist of individuals aged >65 years, approximately 80% of whom will likely require hospitalization for AHF. While no epidemiological studies on this topic have been conducted in Korea, the prevalence of AHF is expected to increase in the future due to the recent increase in the prevalence of risk factors for cardiovascular disease, reflecting the westernization of eating habits, lack of physical activity, and rapid increase in the proportion of elderly people. AHF is also associated with a heavy socioeconomic burden. In the United States, the current annual cost for hospitalizations due to AHF is approximately $34 billion, which is similar to the figures reported in Europe. In Korea, AHF-related expenses associated with an 8-day hospital stay amount to approximately 7.7 million won (about $7,000).

In a Korean AHF cohort, 52% of patients were identified as having de novo HF, while the remaining 48% had decompensated HF. The same study concluded that, at the time of AHF diagnosis, Korean patients tended to be younger (mean age, 69 years) than those in Japan, USA, and Europe; the proportion of men (55%) was slightly higher among Korean AHF patients than among patients from AHF registries in other countries. In this Korean AHF cohort, 59% of patients had hypertension, 35% had diabetes, and 28% had atrial fibrillation. The major cause of AHF was ischemic heart disease (37%), followed by cardiomyopathies (21%), valvular heart disease (14%), and tachycardia-induced cardiomyopathy (11%). The prognosis of AHF is reportedly very poor. A study conducted in the United States reported a 5-year survival rate of less than 1 in 3 patients hospitalized for AHF. Studies conducted in Korea reported similarly poor outcomes: in-hospital mortality, 6.1%; short-term all-cause mortality, 1.2% and 9.2% at 1 and 6 months, respectively; long-term mortality, 15%, 21%, 26%, and 30% at 1, 2, 3, and 4 years, respectively; re-admission rate, 6.4% within 1 month and 24% within 6 months.

INITIAL ASSESSMENT

Symptoms and signs

The traditional clinical approach involves identifying symptoms and signs by taking a clinical history and performing a physical examination in all patients who visit the emergency room with acute symptoms suggestive of HF (Class of Recommendation, I; Level of Evidence, C). The diagnosis can also be made based on objective evidence of pulmonary edema or cardiac dysfunction in patients with signs and symptoms of AHF.

In general, symptoms and signs specific to HF can be divided into two categories: congestion and decreased perfusion of the peripheral tissues. AHF symptoms include orthopnea and paroxysmal nocturnal dyspnea as typical symptoms of congestion, as well as fatigue and
decreased exercise capacity associated with decreased perfusion of peripheral tissues. AHF signs include pulmonary edema, jugular venous engorgement, hepatic-jugular reflux reflex, third heart sound (S3), left downward deviation of the apical pulse, peripheral edema, and decreased urine output. However, it is difficult to discriminate the cause of such symptoms and signs, especially in patients with obesity, advanced age, and chronic lung disease.\textsuperscript{9-13} Therefore, it is recommended that the following medical history be recorded and physical examination be conducted in patients with AHF.

**Orthopnea**
At the bedside, the presence and severity of orthopnea can be easily evaluated if sufficient pillow height is used to achieve a position in which the patient can breathe comfortably. Thus, orthopnea can be defined as: mild or non-existent if the patient can breathe comfortably without a pillow or with minimal elevation of the neck; moderate if the patient can breathe comfortably only when using at least one pillow, with neck elevation of up to 10 cm; and severe if the patient can breathe comfortably only when using at least two pillows.

**Jugular venous distention**
To evaluate jugular venous distention, the patient must sit in a relaxed posture, with the back at an angle of 30°–45° from the horizontal. The neck and chest should be exposed from the middle of the sternum to the antihelix of the ear. Upon turning the patient's neck to one side, jugular venous distention can be measured vertically with illumination. If it is difficult to distinguish the jugular venous pulse from the internal carotid pulse, the hepatojugular reflux can be measured by applying pressure to the right upper quadrant for about 10 seconds and then measuring the time it takes for jugular venous pressure to recover from the transient increase; if the elevated jugular venous pressure persists, right ventricular dysfunction may be suspected. Jugular venous distention, which is measured from the angle of Lewis to the highest point of internal jugular venous pulsation, is considered severe if it exceeds 15 cm.

**Peripheral edema**
Peripheral edema can be examined by applying pressure with the thumb for 5 seconds to the medial malleolus, posterior side of the tibia, or sacrum (in patients who cannot walk). Edema is confirmed if the skin takes longer than 10 seconds to return to the original shape, and is defined as mild edema if observed in only one lower limb or the sacrum, versus moderate edema if observed in the bilateral lower limbs. The patient is considered to have severe edema if a large amount of edema is noted in the lower portion of the calf, if edema extends from the leg to the sacrum (in immobile patients), if pitting edema develops easily and disappears after >30 seconds, or if acute/subacute skin changes including cutaneous distension or cleavage are noted.

**Rales**
Rales are graded as follows: grade 1, unilateral or bilateral rales across the lower third of the lung; grade 2, bilateral rales across the lower half or two thirds of the chest; and grade 3, bilateral rales throughout all lung fields. It is also necessary to distinguish rales from wheezing (stridor) or dry crackles.

**Dyspnea**
Dyspnea is graded according to the New York Heart Association functional classification (Table 3).
Aggravating factors of acute heart failure

In the initial evaluation of patients with AHF, it is important to perform an accurate hemodynamic assessment and to identify the aggravating factors. Common causes of AHF include: acute coronary syndrome, inappropriate control of hypertension, high salt intake, arrhythmia (including atrial fibrillation), medications reducing cardiac contractility, renal impairment, pulmonary embolism, alcohol abuse, worsening of underlying thyroid disease, infection, and worsening of underlying cardiovascular disease (Table 4).14

Because acute coronary syndrome is an important factor that can cause AHF, the patients should be carefully checked for chest pain, changes in the ST segment on electrocardiography, and elevation in blood troponin levels. If necessary, coronary angiography should be performed to exclude the possibility of coronary artery disease as a cause of worsening HF.15 Hypertension is a common cause of AHF exacerbation, especially in women and in patients with HFpEF. Patients with HF who are taking antihypertensive medications can also develop AHF if they suddenly stop their medication.1617 The symptoms

Table 3. New York Heart Association functional classification of dyspnea

| Class | Symptoms |
|-------|----------|
| I     | No limitation of daily physical activity. Ordinary physical activity does not cause symptoms. |
| II    | Slight limitation of daily physical activity. Comfortable at rest, but ordinary physical activity causes symptoms. |
| III   | Marked limitation of daily physical activity. Comfortable at rest, but less than ordinary activity causes symptoms. |
| IV    | Unable to perform any physical activity without discomfort. Symptoms of heart failure at rest. Discomfort increases with any physical activity. |

Table 4. Causes and aggravating factors of AHF

| Causes and aggravating factors |
|-------------------------------|
| 1. Acute coronary syndrome (ACS) |
| 2. Arrhythmias (tachycardia: atrial fibrillation, ventricular tachycardia; bradycardia: conduction disturbances) |
| 3. Excessive rise in blood pressure |
| 4. Noncompliance with recommendations regarding low salt intake, water restriction, or medication |
| 5. Toxic substances (alcohol, recreational drugs) |
| 6. Medications (e.g., non-steroidal anti-inflammatory drugs, corticosteroids, chemotherapeutics with cardiotoxicity) |
| 7. Exacerbation of chronic obstructive pulmonary disease |
| 8. Pulmonary embolism |
| 9. Infection (including infective endocarditis) |
| 10. Surgery and perioperative complications |
| 11. Increased sympathetic tone, stress-induced cardiomyopathy |
| 12. Metabolic/hormonal derangement (e.g., diabetic ketosis, thyroid dysfunction, adrenal dysfunction, and pregnancy- and peripartum-related problems) |
| 13. Damage to the cerebral arteries |
| 14. Acute mechanical cause: myocardial rupture complicating ACS (ventricular septal defect, pseudoaneurysm, free wall rupture, and acute mitral regurgitation), chest trauma or coronary artery intervention, acute native or prosthetic valve incompetence secondary to endocarditis, aortic dissection or thrombosis |

Ponikowski P, et al.; 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal 2016; 37 (27): 2129–2200, doi: 10.1093/eurheartj/ehw128. Reproduced by permission of Oxford University Press on behalf of the European Society of Cardiology. © European Society of Cardiology. AHF = acute heart failure.
may worsen without adequate restriction of water or salt. Atrial fibrillation is common in patients with HF, and an excessively increased heart rate may be a cause of HF exacerbation due to increased left atrial pressure and decreased cardiac output. The use of medications such as calcium channel blockers, non-steroidal anti-inflammatory drugs, corticosteroids, and thiazolidinedione diabetic medications can decrease left ventricular contractility or worsen HF symptoms.

Excessive long-term alcohol consumption will deteriorate cardiac function and can deteriorate HF symptoms. Infections such as pneumonia and septicemia generally increase the metabolic demand or reduce myocardial contractility, which may exacerbate HF symptoms. An exacerbation of renal dysfunction or pulmonary embolism or abnormal production of thyroid hormones can exacerbate cardiac dysfunction. A worsening of pre-existing heart disease such as valvular heart disease would also cause HF symptoms. Therefore, aggravating factors should be assessed and treated in all AHF patients.

**Noninvasive diagnostic tests**

1. The initial assessment of patients with suspected AHF should include 12-lead electrocardiography, chest X-ray, and blood tests to evaluate the levels of blood urea nitrogen, creatinine, electrolytes, and serum glucose, as well as a complete blood count, a liver function test, and a thyroid function test (class of recommendation, I; level of evidence, C).
2. Measuring serum natriuretic peptide levels is useful for making the clinical diagnosis in the presence of signs and symptoms of AHF, and especially useful for the differential diagnosis of AHF in patients with idiopathic dyspnea (class of recommendation, I; level of evidence, A).
3. Echocardiography should be performed in patients with hemodynamic instability or suspected functional or structural heart disease (class of recommendation, I; level of evidence, C).
4. Determining initial serum natriuretic peptide levels is useful for predicting in-hospital mortality and pre-discharge follow up levels is useful for assessing prognosis. (class of recommendation, I; level of evidence, A).
5. Measuring the serum levels of troponin is helpful for predicting in-hospital mortality and for assessing prognosis (class of recommendation, I; level of evidence, A).
6. Measuring the serum levels of ST2, a biomarker of myocardial damage or fibrosis, may be helpful in predicting mortality risk in patients with acute decompensated HF (class of recommendation, IIb; level of evidence, A).
7. The usefulness of treatment based on serum natriuretic peptide levels has not been well established (class of recommendation, IIb; level of evidence, C).

**Symptoms, physical findings, and laboratory findings in decompensated acute heart failure**

The main symptoms of AHF include dyspnea, excessive body fluid retention, and fatigue, all of which are nonspecific findings that may occur in AHF or other cardiovascular diseases. The major symptoms and physical findings suggestive of AHF are summarized in Table 5. Because these symptoms and physical findings can be seen in other diseases, it is necessary to conduct differential diagnosis for pneumonia, pulmonary diseases (chronic obstructive pulmonary disease, pulmonary embolism, pulmonary arterial hypertension), renal impairment, severe infectious diseases, and acute coronary syndrome including AMI.

In patients with suspected AHF, the initial assessment should include general blood tests including biomarkers, electrocardiography, chest radiography, and echocardiography (Figure 2). Typical symptoms and signs of AHF in patients with suspected decompensated
AHF include the characteristic findings of fluid overload (pulmonary edema, peripheral edema); less often, these findings are symptoms associated with reduced cardiac output and decreased peripheral circulation. Because the sensitivity and accuracy of these symptoms and

| Symptom                      | Physical and laboratory findings                                                                 |
|------------------------------|--------------------------------------------------------------------------------------------------|
| Fluid retention              | Orthopnea, paroxysmal nocturnal dyspnea, ascites, symptoms of gastrointestinal tract congestion |
| Tissue hypoperfusion         | Cold sweaty extremities, oliguria, altered mentality (confusion), dizziness                      |
| Hypotension                  | Systolic blood pressure <90 mmHg                                                                  |
| Tachycardia/Bradycardia      | Heart rate >120 beats/min or <40 beats/min                                                       |
| Abnormal respiration         | Respiratory rate >25 breaths/min with use of accessory muscles for breathing; or respiratory rate <8 breaths/min despite dyspnea |
| Hypoxemia                    | Partial pressure of oxygen (PaO₂) in arterial blood <80 mmHg, arterial oxygen saturation <90%    |
| Hypercapnia                  | Partial pressure of carbon dioxide (PaCO₂) in arterial blood >45 mmHg                            |
| Oliguria                     | Urine output <0.5 mL/kg/hour                                                                      |

AHF = acute heart failure.

### Figure 2. Diagnostic approach for AHF.

AHF = acute heart failure; BNP = brain natriuretic peptide; CBC = complete blood count; HF = heart failure; ECG = electrocardiography; LFT = liver function test; NT-proBNP = N-terminal pro-brain natriuretic peptide; TFT = thyroid function test.
physical findings are not high, the above-mentioned basic tests are often needed in addition to the clinical evaluation in order to discriminate the cause.

Baseline evaluation
1) Chest X-ray
Although pulmonary congestion, pleural effusion, and cardiomegaly are the most specific findings related to AHF, chest X-ray scans are normal in up to 20% of patients with AHF. Nevertheless, chest radiography can help detect non-cardiac diseases potentially responsible for the patients’ symptoms.

2) Electrocardiography
Because patients with AHF rarely have normal findings on electrocardiography, this type of assessment is very helpful for identifying the underlying cardiac disease and potential triggering factors.

3) Echocardiography
An immediate echocardiographic examination is necessary only in patients with hemodynamic instability (cardiogenic shock), structural heart disease, or acute life-threatening structural or functional cardiac abnormalities (acute valvular regurgitation or acute aortic dissection). Early echocardiography should be considered in all patients with de novo AHF or for whom cardiac function information is lacking. It is common for patients to undergo echocardiography performed by a specialist within 48 hours of admission. However, the optimal timing of echocardiographic assessment in AHF remains to be established. Repeated echocardiographic examinations are usually not needed unless a change in clinical condition becomes evident.

Laboratory tests
Recent routine blood tests reflect many aspects of the pathophysiology of AHF. Biomarkers for myocardial wall stress, hemodynamic abnormalities, inflammation, myocardial damage, neurohormone changes, myocardial remodeling, myocardial extracellular matrix changes, and myocardial fibrosis are known to provide powerful additional information for the standard diagnosis, treatment, and prognosis of AHF.

1) Natriuretic peptides: the brain natriuretic peptide and N-terminal pro-BNP
Sodium natriuretic peptides are used in the diagnosis or differential diagnosis of AHF, especially in patients with idiopathic dyspnea. The brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) have high diagnostic accuracy and negative predictive value in patients admitted to the emergency room for acute dyspnea, and are not affected by ejection fraction (i.e., are useful in patients with HFrEF or HFpEF). BNP levels were shown to be moderately correlated with left ventricular end-diastolic pressure, and BNP levels at admission were direct predictors of in-hospital mortality, re-hospitalization within 30 days after discharge, and subsequent re-admission and mortality in patients with AHF. Importantly, BNP levels immediately before discharge after HF treatment were good predictors of re-admission and death. Increased levels of natriuretic peptides are very useful indicators of AHF in patients with AHF-related symptoms such as dyspnea (BNP >100 pg/mL or NT-proBNP >300 pg/mL). However, since various cardiac and non-cardiac conditions can result in elevated levels of natriuretic peptides, this criterion alone cannot be used to establish the diagnosis of AHF (Table 6). Thus, clinical characteristics should be considered, along with other laboratory findings.
The levels of natriuretic peptides decrease under treatment for HF, and the magnitude of the decrease is reflected in the extent of clinical improvement. Some studies have focused on optimizing drug therapies to lower natriuretic peptide levels has been investigated whether it can improve clinical outcomes compared to those attainable with standard HF therapy, but the prospective randomized studies conducted to date have not reported consistent results. Therefore, further studies are warranted to clarify the usefulness of these therapeutic strategies.

2) Cardiac biomarkers: troponins

The levels of troponins, which are markers of myocardial necrosis, may be increased in patients with AHF in the absence of AMI or obstructive coronary artery disease, suggesting that myocardial damage or necrosis persists and accumulates. It has been reported that AHF patients with elevated troponin levels are at an increased risk of mortality during hospitalization and after discharge, and that prognosis is better in patients whose troponin levels decrease during treatment, reflecting treatment response.

3) Markers of myocardial fibrosis: soluble ST2 and galectin-3

In combination with natriuretic peptides, soluble ST2 and galectin-3, as biomarkers of myocardial fibrosis, help establish the diagnosis of HF and predict the risk of hospital admission and death. Soluble ST2 is a product of the ST2 gene, a member of the interleukin-1 receptor family. In animals with HF, increased ST2 transcription is associated with progressive myocardial fibrosis and hypertrophy induced by myocardial elongation. In clinical studies, soluble ST2 levels were significantly elevated in patients with AHF, representing a significant predictor of 1-year mortality. Galectin-3 plays an important role in fibroblast activation and fibrosis in animal cell models, and its elevation is associated with long-term survival in patients with HFrEF.

There is clinical evidence to support the future clinical use of biomarkers of myocardial damage and myocardial fibrosis in combination with already established markers such as natriuretic peptides. However, further studies are warranted to clarify the usefulness of such biomarkers for evaluating the prognosis of HF.
**Invasive diagnostic methods**

1. Invasive hemodynamic monitoring using a pulmonary artery catheter should be performed to determine the treatment direction when it is difficult to adequately assess left ventricular filling pressure in patients with dyspnea or hypoperfusion (class of recommendation, I; level of evidence, C).

2. Invasive hemodynamic monitoring can be used in the following cases where symptoms persist despite standard therapy (class of recommendation, IIa; level of evidence, C):
   a. Fluid status, perfusion, and systemic or pulmonary vascular resistance are uncertain
   b. Systolic blood pressure remains low despite initial treatment
   c. Renal function decreases after the start of treatment
   d. An intravenous injection is required to raise blood pressure
   e. Mechanical circulatory assist devices or heart transplantation are considered

3. Coronary angiography and intervention should be performed if ischemia is the suspected cause of HF (class of recommendation, IIa; level of evidence, C).

4. Endomyocardial biopsy may be useful in patients suspected of having a specific disease that may affect treatment decision (class of recommendation, IIa; level of evidence, C).

5. Invasive hemodynamic monitoring is not recommended if pulmonary congestion symptoms improve after diuretic and vasodilator administration in acute non-compensated HF patients with normal blood pressure (class of recommendation, III; level of evidence, B).

6. Routine endomyocardial biopsy is not recommended in patients with HF (class of recommendation, III; level of evidence, B).

---

**Right heart catheterization**

Hemodynamic monitoring is used when it is clinically impossible to assess the fluid status or in patients who are unresponsive to initial therapy, especially if left ventricular filling pressure and cardiac output are unclear. Patients with clinically severe hypotension (systolic blood pressure <90 mmHg or symptomatic hypotension) and patients with renal impairment during initial treatment also undergo invasive hemodynamic monitoring. Patients indicated for heart transplantation or insertion of a mechanical circulatory assist device are also required to undergo right heart catheterization including the measurement of pulmonary vascular resistance, an essential element for evaluating the candidacy of heart transplantation. Invasive hemodynamic monitoring should be used in the following cases: i) cardiogenic shock with an increased demand for vasopressors and a mechanical circulatory assist device; ii) clinically significant non-compensated HF states in which treatment is limited due to uncertainty regarding left ventricular filling pressure, perfusion status, and vascular tension; iii) clinically significant dependence with vasopressor use after the initial clinical improvement; and iv) persistence of severe symptoms after adequate use of standard therapy. On the other hand, routine invasive hemodynamic monitoring is not recommended in patients with decompenated AHF and normal blood pressure who experience symptomatic improvement with diuretics and vasodilators.

**Left heart catheterization**

Left heart catheterization may be useful in patients with left ventricular dysfunction.

**Coronary angiography**

Invasive coronary angiography should be performed in patients who may need coronary artery reperfusion. Coronary angiography is indicated in patients who were previously diagnosed with coronary artery disease and angina or those with ventricular dysfunction and...
severe coronary ischemic findings on electrocardiography or other noninvasive examinations. In patients without a previous diagnosis of obstructive coronary artery disease, the possibility of recurrent obstructive coronary artery disease should be considered if left ventricular dysfunction is present. In these patients, coronary angiography may help confirm the presence and location of coronary artery occlusion. If obstructive coronary artery disease has not been identified as a cause of left ventricular dysfunction, coronary angiography is generally unnecessary unless there is a change in clinical status suggestive of the progression of myocardial ischemia.

**Endomyocardial biopsy**

Endomyocardial biopsy is useful for diagnosing a specific disease that may affect treatment decision. Therefore, endomyocardial biopsy should be considered in patients with rapidly progressing HF or left ventricular function deterioration despite adequate medication. Endomyocardial biopsy should also be considered in patients with acute rejection after heart transplantation, infiltrative myocardial diseases (including primary amyloidosis), or acute myocarditis (especially if giant cell myocarditis is suspected). However, due to the limited diagnostic rate and risk of procedural complications, routine endomyocardial biopsy is not recommended in HF.

**Triage and hospitalization**

AHF includes both acute de novo HF and acute exacerbations of compensated HF. In AHF, the mortality rate is high, and professional medical treatment such as mechanical ventilation is often required. Therefore, it is desirable that the patient be transferred to a specialized medical institution with an intensive care unit. Early diagnosis and appropriate treatment are critical for improving symptoms and stabilizing the patient's condition.\(^{46,47}\)

**Classification of acute heart failure**

The hemodynamic status of patients with AHF can be assessed via history taking and physical examination. The clinical condition is classified based on the findings of bedside physical examination, aiming mainly to detect clinical signs/symptoms of congestion ("wet" or "dry") and/or tissue perfusion ("warm" or "cold") according to the Forrester classification (Figure 1).\(^{48,49}\) Among these categories, “warm-dry” HF, which does not exhibit congestion and is characterized by good perfusion, corresponds to a stable compensated state. Patients with AHF most commonly exhibit congestion and good peripheral perfusion ("warm-wet" HF). Adequate classification of AHF at the initial evaluation is a key to accurately predicting prognosis and choosing the optimal treatment direction.

**Initial assessment algorithm**

Continuous non-invasive monitoring of the patient’s condition is required at the time of the initial evaluation and treatment. The patient’s ventilatory status, peripheral perfusion status, and oxygen supply should be assessed through continuous monitoring of blood pressure, heart rate, oxygen saturation, and urine output.\(^{50}\) In hemodynamically unstable conditions, medication or mechanically assisted circulation therapy should be considered, while mechanical ventilation therapy is required if the respiratory disturbance persists despite appropriate oxygen therapy. To prevent deterioration of the patient’s condition during the initial treatment, it is necessary to identify and treat the triggering factors of HF, including acute coronary syndrome, hypertensive emergency, arrhythmia, acute structural cardiac damage, and acute pulmonary embolism (Figure 3).
1) Acute coronary syndrome

In patients with acute coronary syndrome, early diagnosis and treatment are important and can reduce the incidence of further HF. Patients with congestive HF and acute coronary syndrome are at high risk and require concomitant active reperfusion therapy for acute coronary syndrome.

2) Hypertensive emergencies

AHF can occur with a rapid and excessive increase in arterial blood pressure and mainly manifests as acute pulmonary edema. In the presence of hypertensive episodes, the treatment for HF and that for hypertension should be performed concomitantly. Blood pressure should be reduced aggressively by up to 25% during the first few hours, and the use of intravenous vasodilators with loop diuretics is recommended for this purpose.
3) Arrhythmia (rapid arrhythmia or severe bradycardia/conduction disturbance)

Arrhythmia associated with hemodynamic instability is common in AHF. If serious arrhythmias are noted in AHF patients, they should be stabilized early using medication, electrical cardioversion, or a temporary pacemaker. If the patient has hemodynamic instability due to atrial or ventricular arrhythmias, these arrhythmias should be terminated by electrical cardioversion. If ventricular arrhythmias occur repeatedly, appropriate treatment is required. If arrhythmia is caused by myocardial ischemia, immediate reperfusion therapy is necessary and radiofrequency catheter ablation may be considered in some cases.\(^\text{62}\)

4) Acute mechanical causes

Acute mechanical causes include i) interventricular septal perforation, ventricular free wall rupture, and acute mitral regurgitation resulting from ischemic heart disease, ii) complications due to thoracic trauma, iii) valvular regurgitation secondary to acute endocarditis, and iv) complications due to aortic dissection or thrombosis. Echocardiographic studies play an important role in diagnosis and treatment. In patients with acute structural damage, hemodynamic instability or cardiogenic shock occurs frequently and warrants the use of circulatory assist devices; in such patients, active surgical correction should be considered early.\(^\text{63-66}\)

5) Acute pulmonary embolism

Reperfusion therapy using a thrombolytic agent, percutaneous catheter removal of the thrombus, or surgical embolectomy is recommended in patients with hypotension or shock.\(^\text{67-68}\) Early detection of these triggering factors of HF is important, and treatment should be initiated as soon as possible (within the first 1–2 hours) (Figure 3).

Treatment plan

The initial treatment plan for patients with AHF is created according to the patient’s condition, which is defined in terms of the degree of congestion and peripheral perfusion. The management strategy for AHF is illustrated in Figure 4.

Criteria for hospitalization

In patients with AHF, hospitalization should be considered if there are symptoms or signs of congestion. The indications of hospitalization are listed in Table 7. Few patients are discharged from the emergency room within a few hours due to good response to the initial diuretic therapy. The following criteria should be considered when considering discharge from the emergency room:

- Have the patient’s symptoms improved sufficiently?
- Has the patient’s heart rate stabilized?
- Is orthostatic hypotension absent at standing?
- Is urine output appropriate?
- Is there any deterioration of renal function?
- Is oxygen saturation maintained (>95%)?
If there is persistent dyspnea or hemodynamic instability, it is necessary to observe AHF patients in a space where cardiopulmonary resuscitation is possible. Patients with severe respiratory distress, hemodynamic instability, recurrent arrhythmia, and acute coronary syndrome are considered high risk; it is thus recommended to have such patients monitored and treated in the intensive care unit. Patients who meet one or more of the following criteria are also candidates for intensive care monitoring:

- Decreased oxygen saturation despite oxygen supply (<90%)
- Endotracheal intubation
- Evidence of hypoperfusion
- Use of accessory respiratory muscle during respiration, respiratory rate >25 breaths/min
- Heart rate <40 beats/min or >130 beats/min
- Systolic blood pressure <90 mmHg

**Figure 4. Management strategy for AHF based on the degrees of congestion and peripheral perfusion.**

Ponikowski P, et al.; 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal 2016; 37 (27): 2129–2200, doi: 10.1093/eurheartj/ehw128. Reproduced by permission of Oxford University Press on behalf of the European Society of Cardiology. © European Society of Cardiology.

AHF = acute heart failure.
CONCLUSION

As the prevalence of AHF has been increasing, AHF is a major cause of hospitalization and mortality. In patients with symptoms suggesting AHF, initial assessment should include general blood tests including biomarkers, electrocardiography, chest radiography, and echocardiography. Initial identification and prompt treatment of aggravating factors are crucial in AHF management. The management strategy should be decided based on the patient’s status of congestion and perfusion.

REFERENCES

1. Kim MS, Lee JH, Kim EJ, et al. Korean guidelines for diagnosis and management of chronic heart failure. Korean Circ J 2017;47:555-643.
2. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16.
3. Hugli O, Braun JE, Kim S, Pelletier AJ, Camargo CA Jr. United States emergency department visits for acute decompensated heart failure, 1992 to 2001. Am J Cardiol 2005;96:1537-42.
4. Gloth FM 3rd. The 2005 White House Conference on Aging: a new day for White House conferences on aging and food for the future. J Am Geriatr Soc 2007;55:305-7.
5. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009;53:557-73.
6. Lee SE, Cho HJ, Lee HY, et al. A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry. Eur J Heart Fail 2014;16:700-8.
7. Joffe SW, Webster K, McManus DD, et al. Improved survival after heart failure: a community-based perspective. J Am Heart Assoc 2013;2:e000053.
8. Choi DJ, Han S, Jeon ES, et al. Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the Korean heart failure registry. Korean Circ J 2011;41:363-71.

Table 7. Criteria for hospitalization of patients with AHF

| Recommendation | Signs and symptoms |
|----------------|--------------------|
| Hospitalization required | Hypotension, hypoperfusion, renal impairment, altered mentality |
| | Dyspnea at rest (oxygen saturation <90%) |
| | Acute coronary syndrome |
| | Hypertensive emergency |
| | Significant arrhythmia (tachycardia, bradycardia, conduction disturbance) |
| | Acute mechanical complication |
| | Acute pulmonary embolism |
| Hospitalization should be considered | Increased symptoms of congestion without dyspnea |
| | Symptoms or signs of congestion, including pulmonary congestion |
| | Severe electrolyte disturbance |
| | Concomitant diseases including |
| | Pneumonia |
| | Diabetic ketosis |
| | Cerebral infarction or transient ischemic attack |
| | Recurrent implantable cardioverter-defibrillator shock |
| | Newly diagnosed heart failure |

AHF = acute heart failure.
9. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013;62:e147-239.

10. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2012;14:803-69.

11. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail* 2010;16:e1-194.

12. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. *N Engl J Med* 2001;345:574-81.

13. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. *JAMA* 1989;261:884-8.

14. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. *Arch Intern Med* 2008;168:847-54.

15. Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. *J Am Coll Cardiol* 2009;53:254-63.

16. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. *JAMA* 2006;296:2217-26.

17. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. *Lancet* 2005;366:2005-11.

18. Arcand J, Ivanov I, Sasson A, et al. A high-sodium diet is associated with acute decompensated heart failure in ambulatory heart failure patients: a prospective follow-up study. *Am J Clin Nutr* 2011;93:332-7.

19. Paterna S, Parrinello G, Cannizzaro S, et al. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. *Am J Cardiol* 2009;103:93-102.

20. Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. *Curr Opin Crit Care* 2009;15:392-7.

21. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. *Am J Med* 1991;90:353-9.

22. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? *JAMA* 2005;294:1944-56.

23. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. *Lancet* 1994;343:440-4.

24. Januzzi JL Jr, Sakhuja R, O’donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. *Arch Intern Med* 2006;166:315-20.

25. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. *J Am Coll Cardiol* 2001;37:379-85.

26. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med* 2002;347:1617.
27. van Kimmenade RR, Pinto YM, Bayes-Genis A, Lainchbury JG, Richards AM, Januzzi JL Jr. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. *Am J Cardiol* 2006;98:386-90.

28. Moe GW, Howlett J, Januzzi JL, Zowall H; Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. *Circulation* 2007;115:3103-40.

29. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. *N Engl J Med* 2004;350:647-54.

30. Rogers RK, May HT, Anderson JL, Muhlestein JB. Prognostic value of B-type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure. *Am Heart J* 2009;158:777-83.

31. Cheng V, Kazanegra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. *J Am Coll Cardiol* 2001;37:386-91.

32. Zairis MN, Tsiouasis GZ, Georgilas AT, et al. Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. *Int J Cardiol* 2010;141:284-90.

33. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. *J Am Coll Cardiol* 2004;44:1328-33.

34. Park JJ, Choi DJ, Yoon CH, et al. Prognostic value of C-reactive protein as an inflammatory and N-terminal pro-brain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry). *Am J Cardiol* 2014;113:511-7.

35. Ilva T, Lassus J, Siirilä-Waris K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. *Eur J Heart Fail* 2008;10:772-9.

36. Peacock WF 4th, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. *N Engl J Med* 2008;358:2177-26.

37. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. *J Am Coll Cardiol* 2007;50:667-73.
44. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107:259-67.

45. Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011;108:385-90.

46. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol 2008;52:534-40.

47. Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail 2009;15:256-64.

48. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002;287:628-40.

49. Stevenson LW. Design of therapy for advanced heart failure. Eur J Heart Fail 2005;7:323-31.

50. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version. Eur Heart J 2015;36:1958-66.

51. Rathore SS, Curtis JP, Chen J, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. BMJ 2009;338:b1807.

52. Terkelsen CJ, Jensen LO, Tilsted HH, et al. Health care system delay and heart failure in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: follow-up of population-based medical registry data. Ann Intern Med 2011;155:361-7.

53. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004;109:1223-5.

54. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e139-228.

55. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-425.

56. Elliott WJ. Clinical features in the management of selected hypertensive emergencies. Prog Cardiovasc Dis 2006;48:316-25.
61. Levy P, Compton S, Welch R, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. *Ann Emerg Med* 2007;50:144-52. [PUBMED] [CROSSREF]

62. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J* 2015;36:2793-867. [PUBMED] [CROSSREF]

63. Tepe NA, Edmunds LH Jr. Operation for acute postinfarction mitral insufficiency and cardiogenic shock. *J Thorac Cardiovasc Surg* 1985;89:525-30. [PUBMED]

64. Lemery R, Smith HC, Giuliani ER, Gersh BJ. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. *Am J Cardiol* 1992;70:147-51. [PUBMED] [CROSSREF]

65. Slater J, Brown RJ, Antonelli TA, et al. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? *J Am Coll Cardiol* 2000;36:1117-22. [PUBMED] [CROSSREF]

66. McMullan MH, Maples MD, Kilgore TL Jr, Hindman SH. Surgical experience with left ventricular free wall rupture. *Ann Thorac Surg* 2001;71:1894-8. [PUBMED] [CROSSREF]

67. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J* 2014;35:3033-69. [PUBMED] [CROSSREF]

68. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. *Circulation* 2011;123:1788-830. [PUBMED] [CROSSREF]